Magnetic Resonance-guided Focused Ultrasound (MRgFUS) Treatment of Uterine Fibroid

Abstract

Magnetic resonance-guided focused ultrasound (MRgFUS) is a new treatment modality in treating uterine fibroid. It is noninvasive and can be done as out-patient procedure. It is the least invasive treatment option other than medical treatment. Early reports have demonstrated feasibility and safety. It is efficacious in symptom improve and fibroid volume reduction. This article reviews the principle, patient selection and treatment. Results from early trial and our center are summarized.

Verification of the Ex Vivo Thiel embalmed model for liver treatment with magnetic resonance-guided focused ultrasound (MRgFUS) before clinical practice

“…Two studies involved non-invasive MRgFUS ablations in human breast, in 2001 and 2003 (Hynynen, Pomeroy et al 2001, Gianfelice, Khiat et al 2003) and uterine leiomyoma, in 2003 (Tempany, Stewart et al 2003). In October 2004, the clinical ExAblate2000 system was approved by FDA for uterine fibroid treatments (Chan 2010). Researchers summarized the findings of their clinical trials, pointing out the safety and feasibility of MRgFUS for a potential, non-invasive alternative for tumour treatment (Hindley, Gedroyc et al 2004).…”

“…The ExAblate 2000 (InSightec, Israel) (Figure 2.16) is a FDA approved system utilized for MRgFUS clinical treatment of uterine fibroids. The ExAblate 2000 system has also been used for numerous applications in the research domain, such as the validation of MRgFUS treatment of liver tumours (Hindley, Gedroyc et al 2004, Jolesz, Hynynen et al 2004, Chan 2010, Hynynen 2010. A more analytical description of the ExAblate2000 and its function is given in Chapter 3.…”